JCM
XLRN

Jafra Capital Management’s Acceleron Pharma XLRN Stock Holding History

Jafra Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10,038
Closed -$266K – 95
2017
Q1 		$266K Buy
+10,038
New +$265K 0.11% 62

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jafra Capital Management's XLRN Position: Q2 2017 in Review

Jafra Capital Management sold out of Acceleron Pharma (XLRN) in Q2 2017, closing a stake of 10,038 shares — an estimated $266K sold.

Jafra Capital Management first reported a position in XLRN in Q1 2017 and held it in 1 quarter. The position peaked at $266K in Q1 2017. 128 funds tracked by Wall St. Rank hold XLRN as of Q2 2017.

  • Jafra Capital Management reported no remaining Acceleron Pharma position as of Q2 2017 after selling out during the quarter.
  • Jafra Capital Management sold 10,038 Acceleron Pharma shares in Q2 2017, an estimated $266K.
  • Jafra Capital Management first reported a position in Acceleron Pharma in Q1 2017 and held it in 1 quarter.
  • Jafra Capital Management's Acceleron Pharma position peaked at $266K in Q1 2017.
  • 128 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2017.

Based on Jafra Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.